Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Rosnilimab · ANB-030

Monoclonal antibody · developed by AnaptysBio

Phase 2 Most advanced trial
ANAB Developer
1 Registered trials

What is Rosnilimab?

Rosnilimab (also known as ANB030 and ANB-030) is a drug studied in rheumatoid arthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ANB-030
Drug type
Monoclonal antibody
Therapy area
Immunology
Developer
AnaptysBio, Inc. (ANAB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
93OKX5KD2L

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06041269 Phase 2 Rheumatoid Arthritis Active not recruiting ANAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Rheumatoid Arthritis

More from AnaptysBio

ANB032 Phase 2 Etokimab Phase 2

Follow ANAB, the company behind Rosnilimab

See ANAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ANAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.